M E Caplin
Overview
Explore the profile of M E Caplin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1091
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baudin E, Capdevila J, Horsch D, Singh S, Caplin M, Wolin E, et al.
Endocr Relat Cancer
. 2024 Jun;
31(9).
PMID: 38913539
Prospective data are lacking on early somatostatin analog (SSA) therapy in bronchopulmonary neuroendocrine tumors (BP-NETs; typical carcinoids and atypical carcinoids (TCs and ACs)). SPINET (EudraCT: 2015-004992-62; NCT02683941) was a phase...
2.
Whyand T, Hurst J, Beckles M, Caplin M
Respir Res
. 2018 May;
19(1):79.
PMID: 29716592
Pollution is known to cause and exacerbate a number of chronic respiratory diseases. The World Health Organisation has placed air pollution as the world's largest environmental health risk factor. There...
3.
Mandair D, Vesely C, Ensell L, Lowe H, Spanswick V, Hartley J, et al.
Endocr Relat Cancer
. 2016 Aug;
23(10):L29-32.
PMID: 27521132
No abstract available.
4.
Ramachandran R, Bech P, Murphy K, Caplin M, Patel M, Vohra S, et al.
J Clin Endocrinol Metab
. 2015 Feb;
100(4):1520-8.
PMID: 25664601
Context: Prognosis in patients with neuroendocrine tumors (NETs) is often poor, frequently reflecting delayed diagnosis. Hence, accurate and practical NET markers are needed. Cocaine- and amphetamine-regulated transcript (CART) peptide is...
5.
Caplin M, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, et al.
Ann Oncol
. 2015 Feb;
26(8):1604-20.
PMID: 25646366
Background: Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert consensus document represents an initiative by the European Neuroendocrine Tumor Society to provide...
6.
Khan M, Luong T, Watkins J, Toumpanakis C, Caplin M, Meyer T
Br J Cancer
. 2013 Apr;
108(9):1838-45.
PMID: 23579216
Background: The aim of this study was to compare mitotic count (MC) and Ki-67 proliferation index as prognostic markers in pancreatic and midgut neuroendocrine neoplasms (NENs). Methods: Two hundred eighty-five...
7.
Ramage J, Ahmed A, Ardill J, Bax N, Breen D, Caplin M, et al.
Gut
. 2011 Nov;
61(1):6-32.
PMID: 22052063
These guidelines update previous guidance published in 2005. They have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the...
8.
Khan M, El-Khouly F, Davies P, Toumpanakis C, Caplin M
Aliment Pharmacol Ther
. 2011 May;
34(2):235-42.
PMID: 21585408
Background: Somatostatin analogues are the mainstay of therapy for malignant carcinoid syndrome. There is clear evidence that the once monthly intramuscular formulation, Octreotide LAR, controls symptoms of carcinoid syndrome, and...
9.
Turner N, Strauss S, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al.
Br J Cancer
. 2010 Mar;
102(7):1106-12.
PMID: 20234360
Background: The role of chemotherapy for neuroendocrine tumours remains controversial and there is no standard regimen. Method: We report the outcome for a consecutive series of chemonaive patients with metastatic...
10.
Meyer T, Caplin M, Palmer D, Valle J, Larvin M, Waters J, et al.
Eur J Cancer
. 2009 Dec;
46(3):526-33.
PMID: 20006921
Aim: To evaluate the combination of the gastrin antagonist Z-360 and gemcitabine for advanced pancreatic cancer. Methods: Previously untreated patients with PC were randomly allocated to Z-360 120 mg, 240...